DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome

Information source: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Insufficiency, Chronic

Intervention: Ramipril (Drug); placebo to ramipril (Drug); Ramipril (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Official(s) and/or principal investigator(s):
Oliver Gross, Prof., Study Chair, Affiliation: University Medical Center Goettingen, Department Nephrology and Rheumatology

Overall contact:
Oliver Gross, Prof., Phone: +49 (0)551 39, Ext: 6331, Email: gross.oliver@med.uni-goettingen.de


This is a phase III, multi-centre, randomised, placebo-controlled, patient and investigator-blind study in paediatric patients with early stages of Alport syndrome to assess the safety and efficacy of the ACEi ramipril in slowing disease progression. Alport syndrome stages that describe the extent of renal damage and loss of function are defined as:

- 0 Microhaematuria without microalbuminuria (usually at birth)

- I Microalbuminuria (30-300 mg albumin/gCrea)

- II Proteinuria >300 mg albumin/gCrea

- III > 25% decline of normal renal function (creatinine clearance)

- IV End stage renal failure (ESRF)

Eligible patients with Alport stages 0 and I will be randomly assigned at a 2: 1 ratio to receive once daily ramipril or placebo. In addition, Alport stage II patients may be treated open Label. Eligible patients who, or whose parents/legal guardian refuse randomisation after eligibility is confirmed, and patients who have been treated with ramipril prior to the study, may be treated open-label with ramipril as per protocol. The total number of patients will not exceed 120, with the number of randomised patients not exceeding 60, and the number of patients treated open label from Day 1 of the study aimed to be approximately 60. Randomised patients whose disease progresses to the next disease level during the 3 year treatment period will be unblinded, and open label ramipril treatment will be initiated and continued, respectively, depending on prior treatment randomisation.

Clinical Details

Official title: Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Time to next disease level

Incidence of Adverse Drug Events before progression

Secondary outcome:

Albuminuria after three years

Adverse Drug Events over three years


Minimum age: 24 Months. Maximum age: 18 Years. Gender(s): Both.


Inclusion Criteria:

- Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected

relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss)

- Alport syndrome levels 0, I or II at screening (microhaematuria without

microalbuminuria or microalbuminuria [30-300 mg albumin/gCrea]) or proteinuria >300 mg albumin/gCrea with GFR>80ml/min). Patients with Alport stage II are not subject to randomization but are treated opel label.

- Aged between ≥24 months and <18 years at screening

- Assent from patient and informed consent from parents/legal guardian

Exclusion Criteria:

- Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier

- Alport syndrome levels III, or IV (albuminuria >300 mg/g Crea, creatinine clearance

<60 mL/min, or end stage renal failure [ESRF])

- Known allergies or intolerances to ramipril or related compounds

- Known contraindication for ACEi-therapy

- Additional chronic renal, pulmonary or cardiac diseases

- Pregnancy and lactation

Locations and Contacts

Oliver Gross, Prof., Phone: +49 (0)551 39, Ext: 6331, Email: gross.oliver@med.uni-goettingen.de

University Medical Center Goettingen, Goettingen 37075, Germany; Recruiting
Oliver Gross, Prof. Dr.
Additional Information

Related Information

Starting date: March 2012
Last updated: August 7, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017